Zymeworks Reports $89.2 Million Net Loss and 91% Revenue Decline in Latest Filing

Zymeworks Inc. reported significant financial challenges in its latest quarterly filing, revealing a net loss of $89.2 million for the six months ending June 30, 2026, compared to a loss of $20.3 million during the same period in 2025. The company's revenue from research and development collaborations plummeted by 91% to $7 million, down from $75.8 million in the previous year. This decline was primarily attributed to the absence of substantial non-recurring collaboration revenue, including a $20 million milestone payment from BeOne and other significant fees recognized in 2025.

The company's total operating expenses decreased to $96.3 million for the first half of 2026, down from $102.1 million in 2025. This reduction was driven by lower research and development costs, particularly due to decreased spending on certain programs, including ZW171, which was discontinued in 2025. However, general and administrative expenses rose to $34.4 million, up from $31.9 million, largely due to increased stock-based compensation expenses and professional fees related to the proposed acquisition of Theravance Biopharma.

Zymeworks is in the process of acquiring Theravance, with a merger agreement signed on June 28, 2026. The deal, which is expected to close in the second half of 2026, involves converting each outstanding Theravance share into $17 in cash and a contingent value right. The acquisition is anticipated to be financed through a combination of cash on hand and new debt financing, with a commitment letter already secured for $350 million in senior secured notes.

As of June 30, 2026, Zymeworks had $322.5 million in cash, cash equivalents, and marketable securities, a significant increase from $41.2 million at the end of 2025. This increase was bolstered by a $250 million loan agreement with Royalty Pharma, which allows the company to retain 70% of royalties from its product Ziihera while repaying the loan over time. The company has also initiated a stock repurchase program, having repurchased approximately 1.97 million shares for $49.4 million under its 2026 program.

Looking ahead, Zymeworks anticipates continued operating losses as it executes its strategic plan focused on disciplined capital allocation and advancing its product pipeline. The company aims to leverage its partnerships and collaborations to generate future revenue, particularly from royalties associated with Ziihera, which has received regulatory approvals in multiple jurisdictions. However, the timing and success of these initiatives remain uncertain, and the company acknowledges the inherent risks associated with its development programs.